3/14/18 1
OPHTHALMOLOGY
B Y E R S E Y E I N S T I T U T E
Heather E. Moss, MD, PhD
EFFERENT PATHWAY INVOLVEMENT OF
NEURODEGENERATIVE DISEASE SCIENTIFIC PERSPECTIVE
NANOS ANNUAL MEETING 2018
OPHTHALMOLOGY
Google doc row 18 OPHTHALMOLOGY S ACCADIC PERFORMANCE CAN BE - - PDF document
3/14/18 E FFERENT PATHWAY INVOLVEMENT OF NEURODEGENERATIVE DISEASE SCIENTIFIC PERSPECTIVE Heather E. Moss, MD, PhD NANOS A NNUAL MEETING 2018 OPHTHALMOLOGY B Y E R S E Y E I N S T I T U T E D ISCLOSURES National Eye Institute Research
3/14/18 1
OPHTHALMOLOGY
B Y E R S E Y E I N S T I T U T E
NANOS ANNUAL MEETING 2018
OPHTHALMOLOGY
3/14/18 2
OPHTHALMOLOGY
OPHTHALMOLOGY
3/14/18 3
OPHTHALMOLOGY
Implications of abnormal eye movements Afferent impacts on eye movement measures Leveraging eye movements as a marker of non-
OPHTHALMOLOGY
diagnosis risk assessment monitoring & prognosis
Prevention
Personalized Treatment
3/14/18 4
OPHTHALMOLOGY
MSA gains < PD gains < Control gains with significant overlap
Pinkhardt et al, 2009 Subjects:
23
controls
27 PD 11 MSA-P 8 MSA-C
OPHTHALMOLOGY
MSA MSA PD PD Target Eyes Pinkhardt et al, 2009
3/14/18 5
OPHTHALMOLOGY
Garbutt et al, Brain 2008
Eye position vs. time
OPHTHALMOLOGY
Boxer et al, 2012 latency velocity gain FTD-TDP-43 (12) control (27) PSP (8) CBD (4) Pick, FTP-17 (3) AD (10)
3/14/18 6
OPHTHALMOLOGY
Square wave jerks (in AD) à cerebellar volume
OPHTHALMOLOGY
Boxer et al, 2012 Midbrain volume
3/14/18 7
OPHTHALMOLOGY
Garbutt et al, Brain 2008
OPHTHALMOLOGY
Marker of anatomic site of degeneration Diagnostic feature of disease (mainly for PSP)
3/14/18 8
OPHTHALMOLOGY
OPHTHALMOLOGY
Looking at a scene
Reading
3/14/18 9
OPHTHALMOLOGY
No neurological disease (12 seconds) Parkinson’s disease (21 seconds)
OPHTHALMOLOGY
No neurological disease (12 seconds) Parkinson’s disease (21 seconds)
3/14/18 10
OPHTHALMOLOGY
No neurological disease (12 seconds) Parkinson’s disease (21 seconds) Parkinson’s disease (119 seconds) Jehangir et al (2017), J. Liao PD (n=42) slower than controls (n=80) p < 0.05
OPHTHALMOLOGY
Marker of anatomic site of degeneration Diagnostic feature of disease (mainly for PSP) Scan path analysis may have diagnostic and
3/14/18 11
OPHTHALMOLOGY
OPHTHALMOLOGY
Non-search task Search task (look at trees) Shakespeare et al, 2015
3/14/18 12
OPHTHALMOLOGY
OPHTHALMOLOGY
3/14/18 13
OPHTHALMOLOGY
Marker of anatomic site of degeneration Diagnostic feature of disease (mainly for PSP) Scan path analysis may have diagnostic and
Afferent visual pathway pathology affects eye
OPHTHALMOLOGY
3/14/18 14
OPHTHALMOLOGY
Heuer et al, 2013 Normal (118) Mild cognitive impairment (26) Alzheimers disease (18)
OPHTHALMOLOGY
Seckin et al, 2016
3/14/18 15
OPHTHALMOLOGY
Primitivo et al, 2017 Sequence of targets Anticipatory saccades Correct incorrect
36 12 6
OPHTHALMOLOGY
Marker of anatomic site of degeneration Diagnostic feature of disease (mainly for PSP) Scan path analysis may have diagnostic and counselling
Afferent visual pathway and neuro-cognitive
Potentially useful for testing non-ocular motility
3/14/18 16
OPHTHALMOLOGY
Poor anti-saccades Saccadic intrusions into smooth pursuit Gaze impersistence Voluntary saccade palsy (supranuclear) Reduced Bell’s phenomenon Eyelid opening apraxia
Moss et al, 2012
OPHTHALMOLOGY
Gorges et al, 2015
3/14/18 17
OPHTHALMOLOGY
Proudfoot et al, 2015 antisaccade Correlates with motor score (ALS-FRS) Trail making task control ALS No deterioration over 2 years in 6 subjects